Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06418204 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Study acronym: COSMIC
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 467 → 486 locations
    • Eligibility criteria revised
    • Secondary endpoints: details revised at 4 of 4 entries
  2. Study sites: 462 to 467v28
  3. Study sites: 459 to 462
    • Primary and study completion dates: Aug 2028 to Aug 1, 2028
    v27
  4. Study sites: 450 to 459v26
  5. Study sites: 447 to 450v25
Show 23 earlier versionsHide 23 earlier versions
  1. Study sites: 434 to 447v24
  2. Study sites: 417 to 434v23
  3. Study sites: 408 to 417v22
  4. Study sites: 381 to 408v21
  5. Study sites: 380 to 381v20
  6. Eligibility criteria expanded, about 63 wordsv19
  7. Study sites: 339 to 380v18
  8. Study sites: 280 to 339v17
  9. Study sites: 232 to 280v16
  10. Study sites: 211 to 232v15
  11. Study sites: 191 to 211v14
  12. Study sites: 163 to 191v13
  13. Study sites: 151 to 163v12
  14. Study sites: 87 to 151v11
  15. Study sites: 78 to 87v10
  16. Study sites: 77 to 78v9
  17. Study sites: 1 to 77v8
  18. Start date: Jan 15, 2025 to Jan 30, 2025v7
  19. Eligibility criteria revised
    • Study description expanded, about 1 word
    v6
  20. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2025 to Jan 15, 2025
    v5
  21. Re-verified, no change to tracked fieldsv4
  22. Start date: Aug 2024 to Jan 2025
    • Secondary endpoints: details revised at 2 of 4 entries
    v3
  23. Secondary endpoints: 3 to 4v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Wake Forest University Health Sciences
370 trials monitored
See 46 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
and 3 more diseases
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Trial Details
NCT Number NCT06418204
Lead Sponsor Wake Forest University Health Sciences
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
Related terms Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma
Enrollment 2,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov